Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jan;17(1):104-14.
doi: 10.1111/j.1750-3639.2007.00055.x.

Frontotemporal lobar degeneration: current concepts in the light of recent advances

Samir Kumar-Singh  1 , Christine Van Broeckhoven
Affiliations
Review

Frontotemporal lobar degeneration: current concepts in the light of recent advances

Samir Kumar-Singh et al. Brain Pathol. 2007 Jan.

Abstract

Work done over the past decade has led to a molecular understanding of frontotemporal lobar degeneration (FTLD), a deadly disease that afflicts patients in mid-life. It is a common cause of dementia, second only to Alzheimer's disease in the population below 65 years of age. Neuroanatomical and neurobiological substrates have been identified for the three major subtypes of FTLD and these discoveries have broadened the FTLD spectrum to include amyotrophic lateral sclerosis (ALS). Mutations in MAPT were found to cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), a familial disorder with filamentous tau inclusions in nerve cells and glial cells. FTDP-17 can result in clinical syndromes that closely resemble progressive supranuclear palsy, corticobasal degeneration and Pick's disease. More recently, mutations in three genes (VCP, CHMP2B and PGRN) have been found to cause FTLD with ubiquitin-positive, tau-negative neuronal inclusions (FTLD-U). They explain a large proportion of inherited FTLD-U. It remains to be seen whether dementia lacking distinctive histopathology (DLDH) constitutes a third disease category, as many of these cases are now being reclassified as FTLD-U. Recently, TAR DNA-binding protein-43 (TDP-43) has been identified as a key protein of the ubiquitin inclusions of FTLD-U and ALS. Thus, for familial forms of FTLD and related disorders, we now know the primary etiologies and accumulating proteins. These findings are pivotal for dissecting the pathways by which different etiologies lead to the varied clinicopathological presentations of FTLD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Genotypes, proteotypes and phenotypes of FTLD. Clinical and pathological syndromes of FTD/FTLD constitute a clinicopathologic spectrum. The spectrum continues on the left with Alzheimer’s dementia‐frontal variant and on the right with ALS (*evident on both neuropathology and neuroimaging; ‡the inclusion proteopathy could be TDP‐43). AGD = argyrophilic grain disease; ALS = amyotrophic lateral sclerosis; CBD = corticobasal degeneration; FTD = frontotemporal dementia; FTLD = frontotemporal lobar degeneration; MND = motor neuron disease; PiD = Pick’s disease; PSP = progressive supranuclear palsy.
Figure 2
Figure 2
Pathological features of FTLD‐τ, FTLD‐U and DLDH. Tau (A–C), ubiquitin (D–F) and TDP‐43 (G,H,I) immunostaining is shown on serial sections from superior frontal cortex of Pick’s disease (left panel), FTLD‐U with a PGRN IVS0 + 5G > C mutation (middle panel), and DLDH (right panel). Tau‐reactive cytoplasmic inclusions (arrows) are present in Pick’s disease (A), but absent in FTLD‐U (B) and DLDH (C). Ubiquitin‐reactive inclusions are present in Pick’s disease (D) and FTLD‐U (E), but not in DLDH (F). TDP‐43 commonly stains neuronal nuclei (arrowheads in G,H,I) and also both cytoplasmic and intranuclear inclusions in FTLD‐U (arrow and double‐headed arrows in H). In neurons with inclusions, the normal nuclear staining of TDP‐43 appears reduced. Tau, ubiquitin, and TDP‐43 were stained with mAb AT8 (Innogenetics), rabbit serum against polyubiquitin (Dako, Glostrup, Denmark) and TDP‐43 (R&D systems, Abingdon, UK), respectively, using ABC‐HRP/DAB immunochemical system. Scale bar represents 20 µm. DLDH = dementia lacking distinctive histopathology; FTLD = frontotemporal lobar degeneration.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Amtul Z, Lewis PA, Piper S, Crook R, Baker M, Findlay K, Singleton A, Hogg M, Younkin L, Younkin SG, Hardy J, Hutton M, Boeve BF, Tang‐Wai D, Golde TE (2002) A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma‐secretase cleavage of APP and notch. Neurobiol Dis 9:269–273. - PubMed
    1. Arai T, Nonaka T, Hasegawa M, Akiyama H, Yoshida M, Hashizume Y, Tsuchiya K, Oda T, Ikeda K (2003) Neuronal and glial inclusions in frontotemporal dementia with or without motor neuron disease are immunopositive for p62. Neurosci Lett 342:41–44. - PubMed
    1. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T (2006) TDP‐43 is a component of ubiquitin‐positive tau‐negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611. - PubMed
    1. Babst M, Katzmann DJ, Estepa‐Sabal EJ, Meerloo T, Emr SD (2002) Escrt‐III: an endosome‐associated heterooligomeric protein complex required for mvb sorting. Dev Cell 3:271–282. - PubMed
    1. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez‐tur J, Hardy J, Lynch T, Bigio E, Hutton M (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8:711–715. - PubMed

Publication types